Hoffmann-La Roche, Basel, Switzerland), a selective tyrosine kinase inhibitor that inhibits the epidermal growth factor receptor (EGFR), has been demonstrated to be highly active in patients with non-small cell lung cancer, pancreatic cancer, and several other types of cancer [6]. Here, EGFR is linked to cancer.